Cargando…
Are large simple trials for dementia prevention possible?
New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevent...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047819/ https://www.ncbi.nlm.nih.gov/pubmed/31830268 http://dx.doi.org/10.1093/ageing/afz152 |
_version_ | 1783502187168530432 |
---|---|
author | Whiteley, William N Anand, Sonia Bangdiwala, Shrikant I Bosch, Jackie Canavan, Michelle Chertkow, Howard Gerstein, Hertzel C Gorelick, Philip O’Donnell, Martin Paré, Guillaume Pigeyre, Marie Seshadri, Sudha Sharma, Mike Smith, Eric E Williamson, Jeff Cukierman-Yaffe, Tali Hart, Robert G Yusuf, Salim |
author_facet | Whiteley, William N Anand, Sonia Bangdiwala, Shrikant I Bosch, Jackie Canavan, Michelle Chertkow, Howard Gerstein, Hertzel C Gorelick, Philip O’Donnell, Martin Paré, Guillaume Pigeyre, Marie Seshadri, Sudha Sharma, Mike Smith, Eric E Williamson, Jeff Cukierman-Yaffe, Tali Hart, Robert G Yusuf, Salim |
author_sort | Whiteley, William N |
collection | PubMed |
description | New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations. |
format | Online Article Text |
id | pubmed-7047819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-70478192020-03-03 Are large simple trials for dementia prevention possible? Whiteley, William N Anand, Sonia Bangdiwala, Shrikant I Bosch, Jackie Canavan, Michelle Chertkow, Howard Gerstein, Hertzel C Gorelick, Philip O’Donnell, Martin Paré, Guillaume Pigeyre, Marie Seshadri, Sudha Sharma, Mike Smith, Eric E Williamson, Jeff Cukierman-Yaffe, Tali Hart, Robert G Yusuf, Salim Age Ageing New Horizons New trials of dementia prevention are needed to test novel strategies and agents. Large, simple, cardiovascular trials have successfully discovered treatments with moderate but worthwhile effects to prevent heart attack and stroke. The design of these trials may hold lessons for the dementia prevention. Here we outline suitable populations, interventions and outcomes for large simple trials in dementia prevention. We consider what features are needed to maximise efficiency. Populations could be selected by age, clinical or genetic risk factors or clinical presentation. Patients and their families prioritise functional and clinical outcomes over cognitive scores and levels of biomarkers. Loss of particular functions or dementia diagnoses therefore are most meaningful to participants and potential patients and can be measured in large trials. The size of the population and duration of follow-up needed for dementia prevention trials will be a major challenge and will need collaboration between many clinical investigators, funders and patient organisations. Oxford University Press 2020-02 2019-12-12 /pmc/articles/PMC7047819/ /pubmed/31830268 http://dx.doi.org/10.1093/ageing/afz152 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of the British Geriatrics Society. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | New Horizons Whiteley, William N Anand, Sonia Bangdiwala, Shrikant I Bosch, Jackie Canavan, Michelle Chertkow, Howard Gerstein, Hertzel C Gorelick, Philip O’Donnell, Martin Paré, Guillaume Pigeyre, Marie Seshadri, Sudha Sharma, Mike Smith, Eric E Williamson, Jeff Cukierman-Yaffe, Tali Hart, Robert G Yusuf, Salim Are large simple trials for dementia prevention possible? |
title | Are large simple trials for dementia prevention possible? |
title_full | Are large simple trials for dementia prevention possible? |
title_fullStr | Are large simple trials for dementia prevention possible? |
title_full_unstemmed | Are large simple trials for dementia prevention possible? |
title_short | Are large simple trials for dementia prevention possible? |
title_sort | are large simple trials for dementia prevention possible? |
topic | New Horizons |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047819/ https://www.ncbi.nlm.nih.gov/pubmed/31830268 http://dx.doi.org/10.1093/ageing/afz152 |
work_keys_str_mv | AT whiteleywilliamn arelargesimpletrialsfordementiapreventionpossible AT anandsonia arelargesimpletrialsfordementiapreventionpossible AT bangdiwalashrikanti arelargesimpletrialsfordementiapreventionpossible AT boschjackie arelargesimpletrialsfordementiapreventionpossible AT canavanmichelle arelargesimpletrialsfordementiapreventionpossible AT chertkowhoward arelargesimpletrialsfordementiapreventionpossible AT gersteinhertzelc arelargesimpletrialsfordementiapreventionpossible AT gorelickphilip arelargesimpletrialsfordementiapreventionpossible AT odonnellmartin arelargesimpletrialsfordementiapreventionpossible AT pareguillaume arelargesimpletrialsfordementiapreventionpossible AT pigeyremarie arelargesimpletrialsfordementiapreventionpossible AT seshadrisudha arelargesimpletrialsfordementiapreventionpossible AT sharmamike arelargesimpletrialsfordementiapreventionpossible AT smitherice arelargesimpletrialsfordementiapreventionpossible AT williamsonjeff arelargesimpletrialsfordementiapreventionpossible AT cukiermanyaffetali arelargesimpletrialsfordementiapreventionpossible AT hartrobertg arelargesimpletrialsfordementiapreventionpossible AT yusufsalim arelargesimpletrialsfordementiapreventionpossible |